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Executive Summary 
This deliverable report outlines the activities performed during January 2014- 
June 2016 for the DB-ALM (EURL ECVAM DataBase service on advanced and 
Alternative Methods) enhancements regarding: information content, system 
evolution and innovation, as well as enlarging its outreach. 
In October 2014, the first version of the entirely innovated and revised DB-
ALM was publicly launched that provoked several positive reactions at 
International conferences. Completion is foreseen in 2017, progressively phasing 
out the previous version data sector by data sector. Several initiatives have been 
taken to ensure the state-of-the-art for both the scientific content and 
technological development. The online information content is continuously 
updated with current emphasis on the methods originating from EU funded 
research projects and/or undergoing validation studies towards international 
acceptance. The online information content covers today: 325 method descriptions 
(168 Summaries and 157 Protocols) linked to 82 method evaluations with 3017 
test compounds, 9231 results, and experts` contact details. Further development 
refers particularly to the innovation of the content management system in 
addition to the public DB-ALM internet version. The Method Summary is the main 
data sector of the DB-ALM, providing the key-features of  the comprehensively 
described methods, with regularly updated conent and revised nomenclature. This 
ensures a harmonised framework for adequately describing alternative methods in 
an OECD accepted format, robust and flexible for various types of alternative 
approaches to testing of chemicals, pharmaceuticals, medical devices or 
biologicals.  
A further consolidation and growing interest in the DB-ALM was observed with a 
steady increasing user community and usage, amounting to a total of nearly 
5,000 individual registrations from 82 countries, as well as an enhanced usage 
with over 40,000 accesses to the DB-ALM through the internet during the last 
calendar year. DB-ALM is, for example, referenced in OECD Test Guidelines and 
Guidance documents; scientific books and cited in scientific article, in addition to 
website references of relevant international organisations in and outside of Europe. 
The European Chemicals Agency (ECHA) suggests the DB-ALM as useful 
information source on in vitro methods to be considered for REACH registration 
purposes and the OECD recommended further the use of the DB-ALM for the 
storage and dissemination of method descriptions compliant with the new 
Guidance Document for describing non-guideline in vitro test methods GD 211.  
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1. Introduction 
1.1 Project Deliverable within the WP 2014-2016  
 
The goal of the project Deliverable 8 (D.8) is to provide ready-to-use standardised 
and evaluated descriptions of both in vitro and in silico methods for regulatory and 
research purposes in toxicology and biomedical sciences via web-accessible 
dissemination platforms to facilitate knowledge sharing and their uptake by 
end-users.  
This report refers to activities performed for the DB-ALM between January 2014 
and June 2016 (EURL ECVAM DataBase service on advanced and ALternative 
methods to animal experimentation in biomedical sciences and toxicology) with 
emphasis on in vitro methods, but now also includes non-experimental 
approaches.  
An equivalent report has been defined for the QSAR Model database (JRC102362) and 
both will constitute the final deliverable, deposited in the JRC central repository that 
can be made available on demand. 
Related main deliverables of JRC 816 BioALM/Disseminate1 project: D.2-4 and 7. 
D.2-4 refer to efforts undertaken to enhance and update the information content and 
are summarised in respective reports: JRC98655, JRC100695, JRC100696 available 
from the JRC central repository that can be made available on demand. 
D.7 refers to the development of a harmonised classification/indexing system on key-
features of experimental and non-experimental advanced and alternative methods 
with emphasis on the provision of mechanistic information by EURL ECVAM's 
information systems. The resulting reports will serve as the basis for their future 
interoperability, opening the doors for further applications, such as for Integrated 
Approaches for Testing and Assessment, based on the Integrated Testing Strategies 
or Adverse Outcome Pathways. First report (2016): JRC98655: "Provision of 
Mechanistic Information by EURL ECVAM's Information Systems on Advanced and 
Alternative methods for Toxicological Investigations" is available from the JRC central 
repository that can be made available on demand. 
 
The project implements a mandate of the Directive on the protection of 
animals used for scientific purposes [(2010/63/EU art.48 annex 
VII(2)(d)] with an impact also on: 
 Regulation concerning the Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH) (EC No. 1907/2006) 
 Cosmetic Products Regulation  (EC No.1223/2009) 
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1.2 Rationale 
 
The ready access to suitable, ready-to-use and adequately described methods is 
a prerequisite for their use within decision making processes by regulators and 
scientists or any end-user in the field of biomedical sciences in general, and for 
safety assessment of chemicals or medical devices; or efficacy testing of 
pharmaceuticals, biologicals or vaccines. It supports international efforts to facilitate 
the acceptance of scientific approaches of integrated testing or adverse outcome 
pathways. In particular, regarding the use of novel technologies as advanced tools for 
screening and analysing modes of action, it has a great potential to translate the 
extensive R&D knowledge into a standardised, understandable and reliable source of 
information supporting decision makers.   
Based on a legal requirement, the JRC has established and is managing dedicated 
dissemination platforms for different policy areas and purposes to enhance the 
knowledge about and the uptake of alternative and advanced methods at all stages 
of development and regulatory acceptance.   
The DB-ALM supports in this way the knowledge management and dissemination 
activities of the JRC. This is achieved by making high quality, expert written and 
reviewed information, originating directly from research projects, thematic 
literature reviews on in vitro and other alternative approaches publicly available in a 
ready-to-use format via the internet to all stakeholders, but mainly to: national and 
international authorities, industry, the scientific community and animal welfare 
movements, the Commission services.  
The work on the DB-ALM is primarily focused around two main pillars: 
I. The revision and updates of the online information content including:  
A. New and updated data sheets for the following sectors (page 7): 
- Method Summaries and Protocols (at all stages of development, 
validation and/or regulatory acceptance)  
- Evaluations, EU integrated projects and formal validation studies 
- Test results (generated by documented methods as available) 
- Persons and institutions active in the field of alternative methods 
B. Information standardisation and content criteria (page 12) 
C. Harmonisation of the scientific vocabularies (page 14) 
 
II. System evolution:  
These activities comprise two main branches: ordinary activities (technological 
development of the informatics infrastructure) as well as the extraordinary 
activities (further evolution of the databases, content management 
enhancements and their respective websites, page 19).  
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2. Status at the end of June 2016 
2.1 Public launch of the revised DB-ALM version 
In October 2014 the revised DB-ALM Internet version was formally launched by 
the JRC. It was previously presented on occasion of the 9th World Congress on 
alternatives to animal use in life sciences in August and received throughout positive 
comments during online demonstrations.  
The DB-ALM search interfaces have been redesigned entirely to offer more 
flexibility during data retrieval procedures. The new interface provides the users with 
visible options for clarifying and refining queries based on the controlled scientific 
vocabularies and/or classifications maintained at the JRC and covering the key 
features of advanced and alternative methods developed. The next year will see the 
completion of the remaining sectors in support to phase out completely the current 
version also considering the feed-back resulting from the first release. 
 
Figure 1: Screen capture of the revised DB-ALM Internet version 
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2.2 Users & Usage of the DB-ALM 
Preamble 
The revised DB-ALM version provides more information, such as methods 
abstract, status as well as all data retrieval procedures without the need of 
registration. Even if the core application is public now, the entire transition from the 
previous to the revised database service is made gradually, as more data sectors 
become available. Thus, currently both websites coexist. The login is no longer 
necessary to perform searches on the revised version and therefore less is known, for 
the time being, about the type of the user community in its entirety. Thus, the 
statistics are continuing to being redesigned to informatively and comprehensively 
reflect the usage of this service. Meanwhile, for the two transition years combined 
statistics are maintained to better follow user's interests in the service and are 
captured and reported at the end of each calendar year. 
 
2.2.1 Status, December 2015 
A further consolidation of the DB-ALM was observed with a steady increasing interest 
in the service amounting to a total of close to 5000 registrations over the entire time 
period since first online access was provided. The response of the user community to 
the public launch of the revised DB-ALM in 2014 was immediate and showed a rapidly 
growth of accesses (number of pages visited) that was confirmed in 2015 with over 
42000 accesses, which corresponds to an increase of about the 29% compared to 
the previous year. In particular, the number of data retrieval procedures in the 
Topic Summaries and Methods data sectors had more than doubled in 2015, 
counting over 16500 searches with an increase of about 130% compared to the 
2014. 
Even though data requests could be performed without registration as well as access 
to a subset of additional information is provided, the service still can refer to a solid 
number of new users with 499 new registrations in 2015, being the fourth 
highest during 9 years of public access (see ANNEX II).  
In 2015 the DB-ALM could refer to a total of 2867 unique active users (a person 
who performs search requests in advanced and free text search fields, data sorting 
or navigating the website) performing 10 accesses on average, with a total of 
2661 documents viewed in addition to the abstracts view which does not require 
to login. Furthermore, Newsletters have been sent to over 2000 subscribers in 2014-
2015. 
The major customers of the DB-ALM originate from Italy and the USA  
(c.a.10% each), Germany and France (c.a. 9% each) and Spain and United Kingdom 
(c.a. 7% each), followed by Belgium (c.a. 5%), India, the Netherlands and Brazil 
(c.a. 3% each), and Japan, China and Poland with c.a. 2% each.  
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2.2.2 Information content display/Citations 
Top Ten of the most popular Methods downloaded, Biological Endpoints and 
Topics searched in 2015 are included in the ANNEX II along with the Total 
Accesses per Year (number of pages visited) and the Downloaded documents 
per year. Method descriptions are cited in regulatory documents as well as in the 
scientific literature. More information is available in section 2.6 "Outreach"  
(page 22). 
NOTE: The annexes contain the Registration Tendency showing the evolution of new 
registrations, thus demonstrations of interest in the service, since the first online 
access of the database service. The users' geographical distribution and profile are 
also accessible on the DB-ALM website from the top menu bar at: 
https://ecvam-dbalm.jrc.ec.europa.eu/ (select Use of the DB-ALM from the top 
menu)  
2.3 The Update of the Online Information Contents  
All information content-related activities have been performed according to the 
following priorities: 
1. Regulatory accepted methods  
2. EURL ECVAM recommended and validated methods 
3. Methods from EU Integrated Projects (e.g. SEURAT 1, ACuteTox) 
4. Other emerging methods in development and related updates of DB-ALM 
information contents and its public website  
2.3.1 Method Descriptions 
Method descriptions are provided on two levels of detail by the DB-ALM:  
- Method Summaries are usually defined as an outcome of systematic 
bibliographic reviews on priority topics or more recently refer to original work 
providing adequately documented method description as a stand-alone review 
according to the criteria for data content in place. 
- Protocols always represent original work referring to individual technical 
descriptions of a method to such a detail that allows its transfer to another 
laboratory with no need of additional information. This is ensured by following 
EURL ECVAM standards for information content in a harmonised way. The 
original information is provided by the method experts or owners and reviewed 
by experts from DB-ALM for compliance before its publication.  
At the time of writing the DB-ALM provided 325 Method descriptions online: 168 
Method Summary and 157 Protocol data sheets, covering 9 main topic areas 
(fields of application), further differentiated into more specific categories. 29 Method 
descriptions (comprehensively described ready to-use and stand-alone 
descriptions, together with related information) have been completed which 
were either newly defined, or thoroughly updated in the period January 
2014-June 2016.  
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The overview is provided in the Table 1, and discussed in detail in the text. Further 5 
data sheets are prioritised and are close to finalisation, followed by another 10 data 
sheets with a lower level of prioritisation. 
The various collaborations with colleagues for defining validated methods confirmed a 
best practice of having a Protocol and Method Summary available for every method 
with EURL ECVAM Recommendation (discussed in the section “Support for EURL 
ECVAM Recommendation”, page 13). 
In addition, efforts were made to further develop contacts with the SEURAT-1 
consortium and as an outcome the DB-ALM was chosen to become the 
repository for disseminating particular promising methods developed by 
their projects and to be published as the "Methods Catalogue" by using the DB-ALM 
format for comprehensively describing advanced and alternative methods. Material 
and guidance were provided to the Consortium. In the course of 2015-2016 the 
information on the methods developed within various consortium projects was made 
available to the DB-ALM, leading to 8 publications so far and 5 compiled method 
descriptions that are approaching finalisation. 
In the course of 2013-2015 OECD released a number of new or updates of existing 
Test Guidelines on genotoxicity and local toxicity testing. The information necessary 
to perform an update on the methods involved was collected. First updates were 
completed; others are in various stages of progression, prioritised for finalisation in 
2016-2017.   
Table 1 New and updated methods published in 2014-June 2016, listed by 
topic 
Priority Topic Data sector Title Year 
1 Haematotoxicity Protocol No. 101 Colony Forming Unit-Granulocyte/ 
Macrophage (CFU-GM) Assay (Update) 
2014 
2 Carcinogenicity 
Cell 
transformation 
Method 
Summary 
In vitro BALB/c 3T3 Cell Transformation Assay (CTA)- 
Summary 
2014 
Bhas 42 Cell Transformation Assay in 6- and 96-well 
plates  - Summary 
Protocol No. 156 Bhas 42 Cell Transformation Assay in 6- and 96-
well plates 
No. 137 In vitro BALB/c 3T3 Cell Transformation Assay 
(CTA) 
1 and 3 Local Toxicity Eye 
Irritation 
Protocol No. 157 Ocular Irritection 2014 
Method 
summary 
EpiOcularTM  Assay - Summary 
2015 
Protocol No. 164 EpiOcularTM  Assay 
1 Skin sensitisation 
and allergic 
contact dermatitis 
Method 
Summary 
Direct Peptide Reactivity Assay* 
2014 KeratinoSens* 
Protocol No. 158: Human Cell Line Activation Test (h-CLAT) 
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Priorities: 1 regulatory accepted · 2 recommended and validated · 3 originating from EU integrated projects 
*Method summaries first published in 2014, migrated to the new OECD format and updated in 2015  
No.155: KeratinoSens 
3 Systemic Toxicity Protocol No. 145: Aggregating brain cell cultures for neurotoxicity 
testing, a high content approach: measurements of RNA 
synthesis and gene expression 
2014 
No. 167: HepaRG, repeated and single dose exposure for 
Mitochondrial Health and Lipid Toxicity 
2016 
No. 152:Neural network models for the prediction of 
blood-brain-barrier passage and human intestinal 
absorption 
2014 
Method 
summary 
No. 161 Physiologically-Based Kinetic models 
2015 No. 162 Virtual Cell Assay model 
No. 163: In vitro to in vivo extrapolation  
1 Genotoxicity/ 
Mutagenicity 
Method 
summary 
No. 30 Bacterial reverse mutation test (Ames test) 
2015 Protocol No. 30:  The Ames Test (with S. typhimurium) (update) 
No. 160: Bacterial Mutation Assay (with S.typhimurium 
and E. coli) 
3 Stem cell culture Method 
summary 
No. 165: Differentiation of induced-pluripotent stem 
cells into post-mitotic neurons and glial cells (mixed 
culture) 
2016 
Protocol No. 166: Standard operating procedure for extension 
and propagation of pre-differentiated neural stem cells 
No. 165: Standard operating procedure for 
differentiation of human induced pluripotent stem cells 
into post-mitotic neurons and glial cells (mixed culture) 
1 Effects on 
endocrine system 
Method 
summary 
No. 455: Transactivation Assays to Detect Estrogen 
Receptor Agonists In Vitro with Stably Transfected 
Human Cell Lines 2016 
No. 456: H295R steroidogenesis assay 
3 Mechanistic 
Studies 
Method 
summary 
No 174 : DNA methylation analysis using 
HumanMethylation450k microarray 
2016 
Protocol No 174: DNA methylation analysis using 
HumanMethylation450 microarray 
No 171: Analysis of histone modifications via chromatin 
immunoprecipitation and sequencing (ChIP-seq) 
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The primary focus was put on the definition/updates of Methods with regulatory 
acceptance, undergoing validation, and/or participating in the EU funded research 
projects. The following topics were covered:  
- Skin sensitisation 
New Method summaries and corresponding protocols were written and 
published online for the recently validated “DPRA”, “KeratinoSens” and 
“hCLAT” methods.  In 2015 the method summaries for “DPRA”, and 
“KeratinoSens” were transferred to the new GD211 compliant reporting 
format, revised and republished. Unfortunately due to unforeseeable 
circumstances, the method summary for “hCLAT” could not be finalised yet. 
- Carcinogenicity 
New Method summaries and corresponding protocols were written and 
published online for the recently completed validation studies of two cell 
transformation assays: “BHAS 42” and “BALBc 3T3”. 
- Local toxicity – Eye irritation  
Together with the test submission of the Ocular Irritection® Assay System, 
which supersedes the EYETEX method, a new protocol was published and the 
data sheet on the previous version of the method updated accordingly.   
The EpiOcularTM Eye irritation Assay reached regulatory acceptance as OECD 
TG 492 on 28th July 2015. Accordingly, the existing Methods Summary was 
updated and migrated to the new data format and accompanied by a new 
validation study protocol.  
- Genotoxicity/Mutagenicity 
A review of the bacterial reverse mutation test (Ames test) was finalised which 
included a compilation of a new method summary and a new protocol 
representing the current SOP used by a contract research organization.  
A protocol for the regulatory accepted (OECD TG 487) In Vitro Micronucleus 
method was compiled and sent to the author for approval. Unfortunately, so 
far without response. DB-ALM is searching for another source of an SOP 
compliant with the OECD TG.  
- Systemic Toxicity 
Two new protocols and one update were finalised and published originating 
from the EU integrated project ACuteTox. The remaining seven are close to 
finalisation, awaiting authors final approval.  
In March 2015 the work has started on the Seurat-1 Methods’ catalogue 
and led so far to 8 method descriptions published (JRC100696):  
o Three new method summaries were compiled and published in 
collaboration with EURL ECVAM colleagues directly involved in the 
project. The methods represent three computational approaches 
developed within the COSMOS project.  
o  A method summary and pair of protocols were compiled in 
collaboration with the EURL ECVAM colleagues directly involved in the 
Scr&Tox project. “The differentiation of induced-pluripotent stem cells 
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into post-mitotic neurons and glial cells (mixed culture)” was developed 
at the JRC. The method has also been classified as the first one to be 
registered under the topic Stem cell culture method. 
o The recently finalised report on the “HepaRG, repeated and single dose 
exposure for Mitochondrial Health and Lipid Toxicity” was made 
available to DB-ALM project team in December 2015 and the work has 
started on preparing the respective method summary and a protocol for 
online publication. 
o NOTOX project provided DB-ALM with a method summary and protocol 
for two Methods: DNA methylation analysis using 
HumanMethylation450 microarray and Analysis of histone modifications 
via chromatin immunoprecipitation and sequencing (ChIP-seq). The 
topic Mechanistic Studies was judged as the most appropriate for both 
methods. The respective data sheets were published, with the 
exception of the method summary Analysis of histone modifications via 
chromatin immunoprecipitation and sequencing (ChIP-seq). The draft 
provided too little information to justify a creation of a new datasheet 
and more background information is needed before its completion. 
- Effects on endocrine systems 
A new topic Effects on endocrine systems was set up in the DB-ALM to extend 
the information coverage to a new policy area, namely the area of endocrine 
disruption. In collaboration with the EURL ECVAM colleagues working in this 
area five method summaries were compiled. They are representative examples 
of the assays for testing of Androgen, Estrogen and PPARγ –specific effects 
and steroidogenensis. Two were published (JRC100695) and remaining three 
are expected to be published in the course of 2016. In addition, background 
materials were collected and contact persons identified for additional method 
summaries for studying effects on thyroid signalling.  
Summary of the work progress January 2014-June 2016: 
 
NOTE: The list of methods included in the yearly project planning is based on the 
ready available information on the on-going validation studies, test submissions, 
activities on the OECD level and contacts with individual experts from the research 
communities. In addition DB-ALM staff is aware of several relevant EU research 
projects where alternative methods are being developed/evaluated, however as long 
as no detailed information is available, no planning can be made in advance. Such 
items are not included in the planning table, but will be taken up on case by case 
basis when made available.  
Method Summaries/Protocols processed (44) Work on hold/pending (53) 
Published 
online 
Near 
finalisation  
Work in progress Contact 
lost 
Insufficient information or 
lower priority 
29 5 10 21 32 
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2.3.2 Who’s Who in the field of alternative methods 
The Who’s Who data sector of the DB-ALM was originally established from the 
results of a survey launched by EURL ECVAM on major players in the field of 
alternatives in the various fields of science and regulatory environment to promote 
the exchange of information on advanced and alternative approaches at different 
levels. Today this data sector is mainly composed by the information of those actors 
involved in the preparation, submission and revision of methods included in 
the DB-ALM sharing their respective expertise. Therefore, the data sector 
became an integral part of the Method descriptions. 
In preparation for the periodical update of the whole sector, which is performed about 
every 2 years in line with the Personal Data Protection Regulation of the EU 
(Regulation (EC)  N° 45/2001), a full status assessment of the entire sector was 
made before proceeding with the review which started in December 2014 and was 
concluded in May 2016. Information on the method data sheets will finally be 
adapted, where contact has been lost. 
Periodical review 2014-2016: 
- In the first stage of the periodical review, a total of 131 persons have been 
contacted in October 2014 leading to 53 revised and published records. Those 
who did not reply to the first call and the following reminder, which mainly 
refer to very early registrations without involvement in current method 
developments, were removed from the system. 
- In the second stage a total of 164 persons have been contacted in October 
2015 leading to 14 revised and published records within the same month.  
A reminder was sent to contacts who did not reply to the call.  
 
NOTE: Those who do not reply twice are removed from the service according to the 
policy in place for data protection.  
 
2.3.3  Standardisation of information content and criteria  
The purpose of the DB-ALM Method Summary is to provide adequately documented 
method description as a stand-alone review according to the criteria for data content 
in place. It provides the context for standard operating procedures, which may be 
available from DB-ALM as Protocols, but equally so from other sources. The Method 
Summary includes the intended purpose or actual applications in research or for 
regulatory purpose, its scientific principles, the status of development and 
acceptance, the eventual applicability domain and overall performance as appropriate 
and available, of the method. In contrast, the DB-ALM Protocol addresses the 
practical aspects of the method‟s implementation in a laboratory and routine use, 
provided in standardised and controlled manner. 
2.3.3.1 Compliance with OECD reporting standard for non-guideline methods 
In 2014 the DB-ALM Method Summary was positioned by the OECD as the 
reference format for the description of non-standard experimental methods 
augmented by the expertise of an internationally composed drafting group and their 
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respective organisations.  This resulted in the "OECD Guidance Document for 
Describing Non-guideline in vitro Test Methods (N◦211), an initiative of the 
OECD Advisory Group on Molecular Screening and Toxicogenomics and its programme 
on the development of Adverse Outcome Pathways. In the progress of drafting this 
document the key elements of the method description were defined and finally 
recommended for reporting formats. The final Guidance preserved the information 
elements of the original DB-ALM format for adequately describing alternative 
methods.  
The Method Summary content criteria and format were subsequently refined by 
the BioALM project team (see ANNEX III, page 36) to ensure that all new Method 
Descriptions provided by DB-ALM are visually similar and thus compliant with the new 
OECD reporting standard. At the same time, care has been taken to preserve the 
flexibility of the format to representing all relevant alternative approaches 
for various test materials in addition to chemicals, such as medical devices or 
biologicals, or even for non experimental techniques. 
Practical implementation into the DB-ALM & challenges: 
Once the refined content criteria were implemented in the Content Management 
System of the DB-ALM (see section “Method Summary alignment with the OECD 
Guidance for in vitro methods”, page 20), the project team evaluated possible follow 
up steps. This was done in such a way as to minimise the impact on the database 
structure, in other words to allow for very easy switch between the old and the 
revised format, as illustrated in the Figure 4 (ANNEX IV, page 51). However, prior to 
re-publication each data sheet has to be inspected and adjusted where necessary to 
ensure that the quality after the change to the new format is maintained.  
At present it is not possible to ensure the quality control and migration for all 168 
method summaries in the DB-ALM. Therefore, it was agreed to apply the revised 
format for all new/updated methods published from 2015 onwards.  
In addition, the revised format (intended by the OECD for in vitro methods 
only) was immediately challenged by using it on three in silico methods (from 
Seurat-1) and one in chemico assay (DPRA). The DB-ALM format has proven to be 
robust and flexible for various types of alternative approaches. Some needs 
for further fine tuning were noted, regarding additional free text fields, display of 
contact information and need for support of mathematical formulas. These 
observations will be considered in the further work planning for 2016-2017. 
The revised format has been distributed among the SEURAT-1 consortium members 
as a recommended format for the Methods Catalogue of the Consortium. It was 
also used in a small feasibility study for the endocrine disruptor methods.  
2.3.3.2 Support for EURL ECVAM Recommendation 
Starting from 2013 both documents (Method Summary and Protocol) are to be 
issued together with the EURL ECVAM Recommendation, where the Protocol is 
supplied and revised by the method developer/contact, and the Method Summary is 
compiled by the validation study responsible (or a nominated person) in EURL ECVAM. 
6 such pairs were published so far (see Table 1, page 8). 
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2.4  Harmonised Terminologies & Classifications  
Data compilation and retrieval procedures in the DB-ALM are based on the use of 
classification lists of controlled scientific vocabularies maintained in-house by 
the data dissemination team covering: 
1. Biological endpoints: terms that describe the processes, responses or 
effects assessed completed by the techniques to measure them 
2. Endpoint values: precise values investigated in a given assay 
3. Experimental systems: are the (bio)systems used to study the investigated 
effect 
4. Topic: field of application 
5. Area of concern: chemicals (generic), pharmaceuticals, biologicals, medical 
devices etc. 
6. Models and strategies: type of method used with their sub-categories  
These lists contain hundreds of terms used for describing, classifying and  
indexing or retrieving database contents which have to be maintained, reviewed 
and harmonised, as appropriate each time a new method is added that would require 
a new term and/or is done in the light of new scientific findings. 
Controlled scientific vocabularies are key elements of the revised data retrieval 
approach of the new DB-ALM user interface. The DB-ALM free text search has been 
enhanced with the autocomplete function. When the user starts to enter a search 
term, the autocomplete function uses the classification lists and scientific 
vocabularies to provide suggestions for a successful search. Based on the analysis 
on the website use, since its introduction in 2014, this feature was used in 
approximately 80% of search procedures conducted on the DB-ALM Internet version.  
 
Figure 2: Example of Autocomplete function activated by typing derm in the free text search box  
The activities to standardise the scientific vocabularies are carried out with a clear 
viewpoint of the further development of the Unit's information systems and 
their interoperability to serve future applications, such Integrated Approach to 
Testing and Assessment or Adverse Outcome Pathways [see also D.2, 7 Provision of 
Mechanistic Information by EURL ECVAM's Information Systems on Advanced and 
Alternative methods for Toxicological Investigations (JRC98655)].  
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2.4.1 Biological endpoints 
The Biological endpoints are key elements of the new data retrieval approach of the 
revised DB-ALM launched in 2014. The terms refer to the biological processes, 
responses or effects assessed by a given test method and can be categorised 
by the level of molecular organisation as shown in the Table 2. 
Table 2:  DB-ALM Biological Endpoint 'Clusters' 
Biological endpoint clusters categorised by the level of molecular organisation 
Number 
of terms 
Molecular level Physicochemical or biochemical properties of test substance 19 
Physicochemical properties of test system 2 
Total = 21 
Cellular level Specific features to cultured cells 5 
properties and structures common to all cells 47 
Regulation of cell adhesion 5 
Mutagenesis 16 
Oxidative stress and damage 5 
Total = 78 
Tissue and organ level Blood and vascular system  function and morphology 12 
Central and peripheral nervous system 28 
Connective tissue 1 
Corneal function and corneal inflammation markers 12 
Embryo development: histology and molecular markers 18 
Embryo implantation 2 
Eye and eye lens characteristics 5 
Germ cell maturation 12 
Hepatic functions 21 
Immune responses 9 
Inflammatory responses 3 
Muscle tissue function and morphology 4 
Non-hepatic metabolism (seminal vesicles) 1 
Placental tissue function and morphology 11 
Renal tissue function and morphology 1 
Skin function and morphology 1 
Thyroid tissue function and morphology 2 
Total = 143 
Organism level Conception 1 
Characteristic features of model organisms 26 
Total = 27 
Grand Total = 269 
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The first part of the new DB-ALM content management system was released already 
in 2013 with a dedicated data sector for each of the controlled vocabularies that 
enabled more user-friendly comprehensive revisions by the data specialist which 
started in due course and the biological endpoints (in total over 250 terms) were 
thoroughly revised and updated (see Table 2), followed by with the remaining 
segment "gene expression”. For example, this term was listed as an endpoint in app. 
50 documents and reviewed/updated accordingly.   
 
2.4.2 Experimental Systems 
The list of experimental systems used by DB-ALM until 2015 was heterogeneous and 
could benefit from further harmonisation. Accordingly, the list of controlled terms 
underwent a thorough review for consistency and opportunities for improvement.  
In the first step, the different types of experimental systems were evaluated, with a 
particular focus on the characteristic features (identifiers) used to adequately describe 
each type of a system. The experimental systems recorded by the DB-ALM methods 
fall into several categories:  
 Mathematical models and computerised systems  
 Physico-chemical measurements 
 Cell-free extracts and (bio)polymers 
 Tissue and cell culture including 3 D Models 
 Organs or organ parts used in the ex-vivo studies 
 Complete organisms  
 
In the second step, the existing scientific terminology resources available in the 
public domain were evaluated, relevant for each type of (Experimental) system, to 
define solid reference sources and basic rules on nomenclature.  
When proposing a name for the experimental system, the terminology already in use 
must be taken into account from: 
 Scientific publications 
 Literature databases (e.g. Scopus, Medline, National Agricultural Library, 
Google Scholar)  
 Specialised databases (e.g. cell banks, Tree of Life project, product 
manufacturers and or distributors) 
 Controlled vocabularies/thesauruses (e.g. Medical Subject Headings, US 
National  Cancer Institute – Thesaurus, Cellosaurus)  
 Ontologies (e.g. NCI Thesaurus, Ontology for Biomedical Investigations, 
Experimental Factor Ontology, Cell Line Ontology, Gene Ontology, The 
comprehensive enzyme information system tissue ontology BRENDA). 
 
 
Proposed approach to main categories of experimental systems (selected 
examples): 
 
- Whole organisms / Species 
Both common name and Latin name can be used, unless one of the two is very 
uncommon. For example: when spelling out the names of human cell lines, 
adding Homo sapiens would be unusual, whereas for other animal species 
Latin names are frequently used. Proposed syntax for mouse:  
Mouse (Mus musculus) 
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- Organs and tissues  
Usually the type of tissue is followed by the name of the species, the life stage 
and/or further specifications: 
Conjunctiva (mouse) 
Chorioallantoic Membrane (CAM) (chicken egg) 
Whole blood (human), cryopreserved  
 
- Cell lines 
In order to harmonise different ways of naming the cell lines, the following 
convention is proposed: 
  
name of the cell line  |         species            | cell/tissue type: 
             V79             | Chinese hamster   | lung fibroblast cell line 
 
In total approximately 1000 names of experimental systems were evaluated 
by 2016. 501 terms, linked to method summaries or protocols, were updated to a 
new syntax. Duplicates were merged and unused terms deleted, resulting in 375 final 
terms being updated and republished. A detailed overview of the work was provided 
in the JRC99991 report.  
 
2.4.3 Models and Strategies and Area of Concern 
The other two important classification headings are the “Models and Strategies” 
and “Area of Concern”. The new content management system enables to quickly 
detect data sheets where this information is missing. It was added or updated in 
72 documents, where appropriate.  
The Area of Concern classification list was revised in 2015, to better reflect the 
regulatory distinction between the types of substances. Although from the scientific 
point of view all test substances are chemicals, the applicability domain of a given 
method is usually defined during the validation process and with a specific regulatory 
purpose in mind.  
The users performing their queries often look for methods applicable within a specific 
regulated industry sector. To facilitate this type of search the categories of the test 
materials were re-assigned into 9 main groups:  
1. (Industrial) Chemicals 
2. Pharmaceuticals  
3. Vitamins 
4. Cosmetics 
5. Consumer Products 
6. Food Additives 
7. Environmental pollutants  
8. Nanoparticles   
9. Biologicals  
10. Medical devices.  
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2.4.4 Objective & Applications 
For the purpose of the online application for creating, updating and editing Method 
Summaries, the free text fields Objective & Applications (purpose and type of testing, 
level of assessment) have been replaced by a pick-list, created using the content of 
all public documents (data sheets). The appropriate terms were selected and the 
new improvement to the content management tested.  
 
2.4.5 Bibliography 
Since 19.09.2014, the references can be managed and published entirely from the 
new content management system. This enabled a more efficient management and 
quality control of bibliographic references by the data specialist. After the 
implementation was made available, it was tested and it was started to clean up 
accordingly bibliographic references to be continued in the forthcoming years. 
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2.5 Innovation and System Evolution 
The DB-ALM has been further innovated and evolved from January 2014-June 2016 
regarding: 
 
2.5.1 Software Developments 
2.5.1.1 The public launch of the first release of the revised DB-ALM in 2014 
The revised DB-ALM follows the Commission‟s development standards and industry 
best practices. Based on the experience gained during more than 6 years of 
operation of the DB-ALM on the Internet offered to over 4000 registered users, the 
DB-ALM search interfaces have been entirely redesigned in due course to offer more 
flexibility during data retrieval procedure based on key features of the methods.  
The new interface provides the users with visible options for clarifying and refining 
queries. The user can combine text searches beginning with a classic keyword search 
narrowing the search results with a number of offered choices. Using this progressive 
incremental query construction, users will be enabled to formulate the equivalent of 
a sophisticated query by taking a series of small, simple steps.  
In 2014, following a preliminary (internal) launch and thus broader use, a number of 
functionalities were further refined and completed, the Homepage slightly reviewed 
and functionalities of the content management system adapted. In 2015 further 
developments and refinements where implemented (ANNEX IV, page 49) 
The year 2016-2017 will see the upgrade and/or completion of the revised search 
interfaces and content management system also for the methods’-supporting data 
sectors. 
2.5.1.2 Restructuring formats for Method Summaries and Protocols  
After EURL ECVAM‟s internal request, it was decided that the protocol should not 
include any descriptive sections that can be accomplished by the Method Summary. 
The protocol will maintain those values necessary only for classifying and retrieving 
the document. Thus, the following descriptive sections were deleted from the 
introduction section of the Protocol format: 
- Objective & Applications, Data Analysis/Prediction Model, Test Compounds and 
Results Summary, Modifications of the Method, Acceptance Criteria and 
Proficiency Testing.  
Current Protocols that have content in these fields can still be edited but new 
Protocols do not show these fields anymore. 
2.5.1.3 Adaptations in the light of evolving science and requirements for 
data management 
Much of the work made in 2014-2016 on the database was related to the 
development of the new DB-ALM website and realization of the new requirements for 
the support of the data dissemination of the STU, which include:  
- Changed the Method Summary fields 'Type of Testing', 'Purpose of testing', 
'Level of Assessment' from free text fields to controlled lists. This will allow 
searches to be performed on these fields in the future 
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- Added the 'Exposure regime' section to the Method Summary 
- Added the ability to create and edit publishers and acronyms 
- Add method number for Method Summaries 
- Rèsumès were re-developed with enhanced functionality. They can now exist 
independently of any other item. A Rèsumè can be linked to many Method 
Summaries, Protocols and Validation Studies and a Method Summary or 
Protocol or Validation Study can be linked to many Resumes 
- The „Evaluated Test Method‟ list was updated to include the new functionality 
of Rèsumès related to projects 
- New content management system further developed with the ability to Publish 
and Delete individual datasheets from the database: Topics, Method 
summaries, Protocols, Validation studies, Resumes, Evaluation studies, 
Contacts, Laboratories, Institutes, Bibliographies, Sources, Acronyms, 
Publishers, Experimental systems, Endpoints, Compounds, Test results, Study 
participants, Study labs, Study compounds, Study test results 
2.5.1.4 Method Summary alignment with the OECD Guidance for in vitro 
methods 
Adopting the Method summary format to the OECD Guidance required the 
following changes to be made:   
- Added the ability to display a different layout for a Method Summary based on 
the content criteria version 
- Added a new layout of the Method Summary that matches the format required 
by the OECD 
- Added the ability to assign Contacts to a Method Summary that are linked to 
the who's who data sector to ensure maintenance according legislative rules  
- Added the ability to assign a function for a Contact e.g. Corresponding author, 
Method developer etc. 
- Added the ability to assign a type-value for a Bibliography e.g. Method 
development, General references 
2.5.1.5 User Registration 
The user registration process, forgotten password process and user account page 
were re-written to meet modern development standards and security best practices 
for applications storing user information. 
2.5.1.6 Online applications for providing and updating information contents 
The development of version 2 of the Online Submission application for Method 
Summaries and Protocols has commenced. 
2.5.1.7 Planned activities  
A complete working list is available in the project folder. In particular during the 
forthcoming years the following work has to be carried out and/or completed on the 
content management system, in addition to the finalisation of the public DB-ALM 2016 
version basis for phasing out the previous one (see before):  
- Protocol and Method-Summary submission application and creation of the 
same functionality for the remaining data sectors  
- Migration and updating of Test Results 
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- Management of Who‟s who  
- Content Management for Navigation pages – the text displayed on web pages 
etc.  
- Publication process of website contents 
A document management functionality to interconnect with external documents has 
to be developed and preparation/feasibility evaluations to be done in view of revisiting 
the classification systems in line with the currently ongoing project on harmonising 
classification schemes (addressed by Deliverable 7).  Consequently, at a longer term, 
the integration with the TSAR and related system has to be ensured. 
The website usage statistics needs to be readapted for the DB-ALM 2016 version.  
 
2.5.2  Upgraded server environment  
A new development environment has been upgraded to always match the production 
environment. This allows us to test all website updates and operating system 
upgrades before applying the changes to the production environment. 
 
2.5.3 Documentation 
The work done on the DB-ALM and related activities are documented stating the date 
of entry, priority and completion date of requests in internal project file repository at 
JRC.  
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3. Conclusions and  Outreach 
In addition to the steady increasing user community (close to 5000 registered users 
from 82 countries covering the entire time period since first online access was 
provided; see Section 2.2: “ Users & Usage of the DB-ALM”. page 6), the DB-ALM has 
been presented at the following events and/or using the following communication 
channels: 
1. At the end of 2014 the OECD has approved the "Guidance for describing 
non-guideline in vitro test methods" (N° 211) for methods at all stages of 
development, including at early stage. It was based on the format in use by 
the DB-ALM augmented with the expertise of an internationally composed 
drafting group and their respective organisations. The OECD recommended 
the use of the DB-ALM for the storage and dissemination of methods 
described according to it. 
2. Public awareness was raised by sending a series of newsletters to more 
than 2000 DB-ALM newsletter subscribers.  
3. Growing interest and use of the DB-ALM information content has been 
observed. For example: 
 DB-ALM is referenced in 6 OECD Test Guidelines and 2 OECD Guidance 
documents (for more details refer to “ANNEX V: Bibliographic Citations“ 
page 53)  
 more than 160 scientific books and journal articles included numerous 
references to the DB-ALM documents [Google Scholar and SCOPUS 
search performed on 22-06-2016 (for more details on the most recent 
publications refer to ANNEX V: Bibliographic Citations “ page 53)  
 the European Chemicals Agency (ECHA) indicates the DB-ALM as useful 
information source on in vitro methods to be considered for REACH 
registration purposes 
 the National  Brazilian network for Alternative Methods (RENAMA) 
features DB-ALM on their homepage, and a substantial number visits 
to the DB-ALM are redirected from this page. A complete list of the 
websites referring most of the visitors to the DB-ALM are listed in the 
ANNEX V: Bibliographic Citations” (page 70) and include not only search 
engines but also the Swedish 3R‟ centre, e-Learning platform for 
laboratory animal science LAS interactive and the Shiseido cosmetic 
company.  
 the US Health and Environmental Sciences Institute (HESI) emphasises 
the usefulness of the JRC database.  
4. SEURAT-1 consortium has chosen the DB-ALM to be the repository for 
descriptions of particularly promising methods developed by the participating 
projects. The revised DB-ALM format has been adopted as the recommended 
format for the Methods Catalogue of the consortium. 
5. At the 9th World Conference for alternatives to animal use in August 
2014 (close to 1000 attendees) the new search interface of the DB-ALM was 
presented and tested by the individual visitors at the stand of the JRC in the 
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exhibition area and can refer to only positive feedback documented in a 
questionnaire. 
A poster and oral presentation were given as well on the EURL ECVAM 
dissemination activities and the session on dissemination via databases co-
chaired.  
6. The poster and leaflet of EURL ECVAM database services were included in the 
online Poster and Flyer collection  “Animals used for scientific purposes” on 
the DG Environment website and received positive responses through social 
media: 
http://ec.europa.eu/environment/chemicals/lab_animals/pubs_posters_en.ht
m 
7. At the 51st Congress of The European Societies of Toxicology in September 
2015 (EUROTOX 2015, app. 1500 attendees) the EURL ECVAM information 
systems were presented to individual visitors at the stand of the JRC in the 
exhibition area and received a very positive feedback. 
8. At Workshop: “Mechanisms, markers and models – the 3M strategy in 
risk assessment” in October 2015 (organised jointly by SSCT and Swetox, 
61 attendees) the poster on EURL ECVAM dissemination activities was 
presented and the Content Criteria for Method Summaries were distributed to 
the participants.  
9. In order to provide a better visibility of the BioALM/STU-Disseminate WPK1 
project (JRC 816) within the Commission, a dedicated project space was 
created on Connected. It offers background information, documents, the links 
to all information systems and the possibility to interact directly with the 
project team (accessible to JRC personnel only):  
https://connected.cnect.cec.eu.int/groups/816-bioalm-dissemination 
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Figure 3: Screen capture of the BioALM Dissemination project space on Connected 
(last access 10 June 2016). 
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4. Access to the deliverable 
 
Public access to the DB-ALM:  
https://ecvam-dbalm.jrc.ec.europa.eu  
 
Public access to the revised DB-ALM version: 
https://ecvam-dbalm.jrc.ec.europa.eu/ 
 
DB-ALM staging environment providing access to all applications and to the content 
management systems (accessible to JRC personnel only): 
 https://staging-ecvam.jrc.ec.europa.eu/dbalm-staging/ 
 
 
5. Contacts 
 
Helpdesk: dbalm-contact@jrc.ec.europa.eu  
DB-ALM Responsible: annett.janusch-roi@ec.europa.eu  
 
 
6. Abbreviations 
 3D – three dimensional 
 DB-ALM – EURL ECVAM DataBase service on ALternative Methods to animal 
experimentation 
 EU – European Union 
 EURL ECVAM - European Union Reference Laboratory for alternatives to animal 
testing. Formerly a part of the Systems Toxicology Unit at JRC. As of 
01.07.2016 its duties are transferred to the Chemical Safety and Alternative 
Methods unit (F.3)  
 JRC – Joint Research Centre 
 OECD – The Organisation for Economic Co-operation and Development 
 R&D – Research and Development 
 SEURAT-1 – Safety Evaluation Ultimately Replacing Animal Testing 
 WP – Work Program 
 WPK - Work Package 
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7. Annexes 
 
 
I. DB-ALM Newsletters 
II. DB-ALM User Community 
III. Method Summary in OECD Compliant Format 
IV. Software developments (extract) 
V. Bibliographic Citations  
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7.1 ANNEX I: DB-ALM Newsletters 
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October 2014  
 
 
1. DB-ALM Updates, October 2014 
DB-ALM 2014 Version – now online 
In line with the commitment of the Joint Research Centre to enhance the 
dissemination of knowledge on advanced and alternative methods, the EURL 
ECVAM is aiming at constantly improving its services. We now have the pleasure 
to inform you that the entirely revised DB-ALM 2014 Version is available online.  
It provides a completely redesigned data retrieval approach where more flexibility 
and support is offered. This version was presented during the 9th World 
Conference on Alternatives and Animal Use in the Life Sciences in Prague this 
August where first positive feedback has been collected. We wish you happy 
navigating!  
2. Updated DB-ALM Information Content 
Together with the revised DB-ALM 2014 version and since our last communication, 
the following method descriptions have been published for in vitro methods 
compliant with regulatory requirements and/or undergoing validation by the EURL 
ECVAM in the areas of Carcinogenicity, Eye Irritation and Skin Sensitisation:  
 In vitro BALB/c 3T3 Cell Transformation Assay (BALB/c 3T3 CTA)  
(Method Summary and Protocol No. 137)  
 Bhas 42 cell transformation assay in 6- and 96-well plates  
(Method Summary and Protocol No. 156)  
 Ocular Irritection® Assay System (Protocol No. 157)  
 Human Cell Line Activation Test (h-CLAT) (Protocol No. 158) 
Access: DB-ALM 2014 Version  
 
European Commission - Joint Research Centre 
Institute for Health & Consumer Protection 
European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) 
EURL ECVAM DataBase service on ALternative Methods to animal experimentation (DB-ALM)  
DB-ALM website: http://ecvam-dbalm.jrc.ec.europa.eu 
You received this message because you subscribed to the "DB-ALM News" mailing list. To unsubscribe login to the DB-
ALM web site here and change your profile. View our Privacy Policy  
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April 2015 
 
Updated information content on QSAR methods, April 2015  
We have the pleasure to inform you that, in addition to the updated information 
on in vitro methods, computational methods which are publicly available 
from EURL ECVAM's Information Systems, will be also covered in our future 
communications. 
  
Ten new reports have been published in the JRC QSAR Model Database that uses 
an internationally recognised format to provide key information on models which 
are all peer-reviewed before publication. The new reports refer to the following 
topic areas: 
 six reports for the main endpoint Human health effects with the following 
QSAR inventory numbers:  
Q35-50-46-429; Q32-48-43-426; Q32-48-43-425; Q31-47-42-424; Q29-
44-39-423; Q28-43-38-420  
 four reports for the main endpoint Ecotoxic effects with the following 
QSAR inventory numbers:  
Q33-49-44-427; Q34-49-44-428; Q19-46-41-422; Q30-45-40-421 
The complete list of published QSAR models (80 in total) can be freely 
downloaded from the JRC QSAR Model Database list of published reports.  
  
More information on QSAR models and free download of all published QSAR 
reports can be obtained directly from the JRC QSAR Model Database . 
 
European Commission - Joint Research Centre 
Institute for Health & Consumer Protection 
European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) 
EURL ECVAM DataBase service on ALternative Methods to animal experimentation (DB-ALM)  
DB-ALM website: http://ecvam-dbalm.jrc.ec.europa.eu 
You received this message because you subscribed to the "DB-ALM News" mailing list. To unsubscribe login to the 
DB-ALM web site here and change your profile. View our Privacy Policy  
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August 2015 
 
 
DB-ALM now provides non-guideline in vitro test methods in OECD 
compliant format, August 2015  
The JRC's European Union Reference Laboratory for Alternative Methods to Animal 
Testing (EURL ECVAM) has adapted the format of DB-ALM, its unique public 
database on alternative methods, to fully comply with the OECD guidance for 
describing non-guideline in vitro test methods. 
JRC/EURL ECVAM scientists were important contributors to the formulation of 
Guidance Document No.211 which was released by the OECD last December 2014. 
The guidance was motivated by a growing awareness within the scientific and 
regulatory communities that data derived from in vitro methods (e.g. mechanistic 
information) can have considerable value in supporting chemical safety 
assessment, even in cases where the in vitro method is not included within an 
OECD Test Guideline or has not been formally validated, provided the method is 
properly described in terms of its scientific/technical basis and its reliability and 
relevance.  
Making such method descriptions readily available via the widely accessed DB-ALM 
(over 4400 registered users from 82 countries) will encourage their uptake and 
use in a variety of sectors for multiple applications, such as chemical toxicity 
screening or within integrated approaches to chemical safety assessment.  The 
data generated by end-users may also aid the retrospective validation of methods 
intended for more routine regulatory use which may eventually be incorporated 
into future OECD Test Guidelines. DB-ALM already contains over 300 entries for 
alternative methods, at all stages of development and with various levels of detail 
(summary descriptions or detailed protocols). It covers mainly in vitro methods, 
but also includes non-experimental approaches. 
Access: 
  DB-ALM:  http://ecvam-dbalm.jrc.ec.europa.eu 
 OECD Guidance document for describing non guideline in vitro test methods 
no 211 
 
European Commission - Joint Research Centre 
Institute for Health & Consumer Protection 
European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) 
EURL ECVAM DataBase service on ALternative Methods to animal experimentation (DB-ALM)  
DB-ALM website: http://ecvam-dbalm.jrc.ec.europa.eu. 
You received this message because you subscribed to the "DB-ALM News" mailing list. To unsubscribe login to the 
DB-ALM web site here and change your profile. View our Privacy Policy   
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7.2 ANNEX II : DB-ALM User Community/Usage 
(31 December 2015)1 
 
 
 
 
 
 
 
 
 
 
  
                                           
1 NOTE: In September 2014 the revised DB-ALM version was released that allows data retrieval and 
access to method features also without registration. 
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DB-ALM usage (1/5) 
(31 December 2015) 
ANNEX II  
Page | 33  
 
   
5897 
25054 
27923 
19103 
15994 
18008 18154 
38090 
32463 
42036 
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
N
u
m
b
e
r 
o
f 
p
a
g
e
s
 v
is
it
e
d
 
Total accesses per year DB-ALM usage (2/5) 
(31 December 2015) 
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NB: Since 2014 information on key features of methods is provided without the need for registration/download 
DB-ALM usage (3/5) 
(31 December 2015) 
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DB-ALM usage 
(4/5) 
(31 December 2015) 
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7.3 ANNEX III: 
 
Method Summary in OECD Compliant Format: 
Criteria for Data Content 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Last Update: January 2015 (v.10) 
 
 
© European Union 2006-2016 
https://ecvam-dbalm.jrc.ec.europa.eu 
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The DB-ALM Criteria for Data Content are based on the analysis of common 
descriptors from hundreds of different non-animal experimental methods and 
techniques collected for the purpose of providing public access via the EURL ECVAM 
DataBase service on Alternative Methods (DB-ALM).  
These criteria shall ensure the comprehensive descriptions of advanced and 
alternative methods at all stages of development, validation and/or acceptance in the 
field of biomedical sciences and toxicology used for various compounds and 
materials in research and for regulatory purposes. 
The present revised criteria (v10) are compliant with the “OECD Guidance for 
describing non-guideline in vitro test methods” developed to facilitate their 
consideration in regulatory applications. 
However, the DB-ALM format is designed to be flexible and broad enough to allow 
for summary descriptions of both experimental and non-experimental methods, as 
appropriate, also for non-regulatory applications (see NOTE on page 3).  
 
 
The DB-ALM is operated by the European Union Reference Laboratory for 
Alternatives to Animal Testing (EURL ECVAM) of the  
European Commission’s Joint Research Centre. 
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NOTE: The content criteria are periodically reviewed to respond to emerging needs. Not all fields or 
sections are applicable to all methods equally. Options for free text additions are always offered by the 
system. It is the responsibility of the author to provide content where relevant and as appropriate related 
to a precise method. A review for consistency and compliance of the content provided with the criteria in 
place is always performed before any method will be published via the DB-ALM. Any comment or 
suggestions for amendments should be sent to dbalm-contact@jrc.ec.europa.eu .
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Method Name: name of the method 
Summary: One-two sentence summary on the method features 
1. General information 
Method developer (s)2 
- Name, Institution, Country 
Date of data sheet creation 
Last version number 
Last update 
Notes:             
Proprietary and/or confidentiality issues 
Short paragraph containing information on intellectual property rights (if applicable), 
including the information whether the method details or any equipment, materials, 
software or mathematical models needed to carry out the procedure is copyright 
protected, trademarked, access- restricted or undisclosed.  
If a distribution of the method or any of its components is limited by a copyright protection 
or confidentiality agreement, this should be indicated with a reference to the holder of the 
intellectual property right. 
Assay throughput 
If applicable, indication of the throughput of the assay and/or likely resource intensity 
should be given, e.g. low (manual assay, one chemical tested at a time), low-moderate, 
moderate, moderate-high, high throughput/footprint (e.g. in 96 well-plate and higher), and 
qualify with e.g. approximate number of chemicals/concentrations per run. If appropriate 
indicate whether a manual assay could be run in a higher throughput mode 
Status  
Should be compiled with the appropriate sections, as applicable: 
 
In development: 
Indication if the method is under development and the estimated timeline for completion 
as far as possible 
Known laboratory use: 
Summary of the current and/or past use of the method by different research groups 
Participation in evaluation studies: 
List of the main studies conducted using the method  
Participation in validation studies: Indication whether the method has undergone any 
formal validation (as defined in OECD Guidance Document No. 34) or similar activities  
Regulatory acceptance/compliance/standards: 
Indication of any existing regulatory application and of the toxicological hazard endpoint 
being addressed by the method, as appropriate. If applicable, the relevant guidelines 
and/or on-going guideline developments with indication of the step(s) within the regulatory 
acceptance process (Draft Test Guideline or accepted) or any other compliance with 
                                           
2 Affiliation details are listed at the end of this document.  
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(inter)national standards should be listed. The details and rationale should be provided in 
the next section: Purpose of the Method. 
2. Method Definition 
 
Purpose of the Method 
 
Type of Testing : e.g. partial (full) replacement, adjunct 
(3Rs relevance) 
Level of Toxicity Assessment : e.g. toxic potential, dose response, toxic 
potency, hazard 
Purpose of Testing : e.g. LOEL, mechanistic study, screening, 
priority setting, classification and 
labelling, biocompatibility, quality control 
or efficacy testing  
NOTE: These terms are part of a controlled vocabulary used for data retrieval purposes 
during dissemination of the DB-ALM based on the information provided below. 
Context of use & potential applications 
Short paragraph on the intended use referring to the particular investigation with a 
proposal for the practical applications of the method:  
- Regulatory applications (e.g. safety testing of chemicals REACH, classifications 
under GHS, cosmetics and pharmaceuticals regulation such as international 
guidelines and requirements for pharmaceutical (ICH) and veterinary (VICH) 
product registration, biocompatibility testing of medical devices, safety evaluations 
of nanomaterials, quality control of vaccines) 
and/or 
- Non-regulatory purposes (e.g. cell culture studies, exploratory research) 
 
The following supporting information should be provided to describe the level of 
scientific confidence for the previously suggested uses, such as:   
- An alternative to an existing method/approach, provision of novel information for 
regulatory decision making or non-regulatory uses  
- Positioning in the context of any existing regulatory hazard endpoint (i.e. adverse 
outcome), such as support to grouping of substances to support read-across and 
weight of evidence evaluations, priority setting, screening, mechanistic activities  
- Indication of all suggested applications, e.g. either based on experimental evidence 
or reliable prediction model; or if it is wider, providing a justification for this (and 
referring to the 'Applicability' section as appropriate)  
- Its possible use in test batteries, integrated approaches to testing and assessment 
(IATA)/integrated testing strategies (ITS), or adverse outcome pathways (AOPs) 
- In case of non-regulatory applications exhaustive information on the methods 
purpose and eventual evidence should be provided 
NOTE: If the information specified above is not available to such a detail, the objectives 
and proposed application/s of the method should be summarised in one paragraph laying 
down the intended purpose/context for its use. The linkage between the biological 
endpoint investigated and the suggested use(s) should always be given. 
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Scientific Principle of the Method 
Short paragraph containing information on the origin and the basic scientific principles of 
the method including the:  
- scientific rationale and the history of the method development 
- biological basis (e.g. modelling a specific organ, e.g., reconstituted human skin 
models) 
- mechanistic basis of the method (i.e. modelling a particular mechanism by  
biochemical parameters e.g., the Haemoglobin Denaturation Test for Eye 
Irritation)  
- toxicological/biological relevance (i.e. mode of action addressed, toxicological 
endpoints); in case the measured biological endpoint refers to a molecular 
initiating event (MIE) or any key event (e.g. mechanism of action, AOP), 
together with the context, also at which level of biological organisation the 
method can be attributed (e.g. sub-cellular, cellular, tissue and organ or 
individual) including the anchor point within an AOP (as applicable) 
NOTE: Any biological endpoint(s) investigated and indicated should always be put in the 
context concerning biology/physiology leading to the in vivo response or effects. 
 
Procedure Description 
Biological endpoint & Endpoint measurement 
Indication of the biological processes, responses or effects assessed and techniques 
used for their measurement with a short description, such as e.g. “corneal opacity 
measured using an opacitometer”. 
NOTE: Biological endpoint terms will be reviewed against DB-ALM controlled vocabulary. 
Biological endpoint value 
Precise endpoint assay investigated (e.g. IC50, NOEL) if applicable  
Experimental system 
Name, category and species source of the material for the endpoint being measured, 
such as “freshly isolated bovine cornea" (organotypic) 
NOTE: Terms will be reviewed against DB-ALM controlled vocabulary  
NOTE: Provide information if the material is readily available commercially or whether it is 
developed in the laboratory on site (e.g. cell suspension from tissue). Indicate 
source/manufacturer of the biological material used.  
Metabolic competence 
If applicable, indicate to which extend the system can be considered metabolically 
competent, either by itself or enzymatic fractions added. Indicate the name of the 
system used  
 
Exposure regime 
Application volume : Volume of the test substance applied and volume unit 
Concentration  : Concentration of test substance applied  
(dose and/or min and max used) 
Dosage  : Amount of substance administrated  
(dosing and/or min and max dosage used) 
Application type : Single/repeated dose or continuous dosing 
Exposure Time : Period in time unit of contact between the tested  
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    substance and the experimental system 
Controls  : Negative and positive controls and other references or 
Standards used 
Other Details :  Other useful parameters not listed above, e.g.: name of  
  the method used for detecting the test substance  
Summary  
A short description of the basic procedure; e.g. the exposure regime, including 
observation frequency, replicate number, and key steps, together with the references to 
the appropriate section of the DB-ALM protocol (as applicable). A DB-ALM Method 
Summary may apply to multiple protocols with different exposure regimes where the 
structured Exposure regime section above cannot be filled in detail, but an overall outline 
should be given here.  
 
Quality/Acceptance Criteria 
Whenever appropriate, information should be provided on the availability of acceptance 
criteria and quality assurance in place in the form of a short and easily overseeable list, as 
it pertains to, such as: 
- Criteria for experimental system acceptance 
- Criteria for acceptance or rejection of experimental data  
- Experimental data storage/archiving done 
- Internal reference standards/chemicals/performance benchmarks 
- Equipment used/calibration programmes 
- Quality systems in place, such as Good Laboratory Practice (GLP) or Good Cell 
Culture Practice (GCCP), ISO 9001 or similar. 
 
 
 
 
Data Interpretation and/or Prediction Models 
Data analysis  
Summary of the data analysis procedures applied to the raw data, specialised software  
(if applicable), statistical approach used and rationale for its choice. If applicable, 
information on data interpretations and/or evaluations should be given. 
 Specification of the software name and version used for data analysis 
 
Prediction model (PM)  
If appropriate, the rules for the prediction of the in vivo toxicity potential from in vitro test 
data or any other PM used should be provided, including any eventual criteria for the 
classifications. Detailed descriptions of large and complex models can be attached as 
supporting document(s) and references to publications that describes it into detail be 
made. 
 Specification of the software name and version used for algorithm/prediction model 
generation. 
The prediction model could part of a more complex PM that relies on different methods 
(e.g. IATA, test battery). In such case, it is recommended to provide this information 
separately with individual method descriptions or by compiling a project/study summary in 
the DB-ALM where it can be described entirely or make reference to relevant publications. 
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In some cases it may be helpful to consider the intended purpose of the prediction model 
in the context of an AOP: e.g. a desire to predict a given outcome.  
 
3. Method Performance 
 
The information on the robustness of the method i.e. the reliability of the (experimental) 
results and the prediction capability of the model used is expected in this section.   
Information is to be provided under the following paragraphs (as appropriate): 
 
Robustness of the Method 
The information may be available at various levels of detail according to the 
development status and the nature of the method. Information on repeatability, 
reproducibility and between laboratory transferability should be reported if known, or 
any other information relevant for the evaluation of the method depending on the 
method’s purpose. 
Within-laboratory reproducibility 
Evidence of the agreement among results obtained from testing the same set of 
compounds over time using the same protocol in one laboratory, including an 
explanation on possible sources of variability (if applicable). 
Between-laboratory transferability and reproducibility 
The following information should be provided (if known): 
- an estimation of the amount of training that is necessary to establish the test method in 
a naïve laboratory  
- obstacles or difficulties that may impact on the transferability of the test method, e.g. 
level of complexity of some procedures in the protocol(s). 
- the results of the assessment of the between-laboratory reproducibility of experimental 
data 
General performance measures 
For methods, where between-laboratory transferability and reproducibility studies might 
not be applicable, available and/or feasible, it may be helpful to include information on 
other performance measures or similar under this section. If applicable, the explanations 
of the curve fitting process together with the assumptions used to determine the 
goodness-of-fit and any limitations related to the data analysis, as well as any other 
means for evaluating the performance of a method can be provided here. 
 
Test Compounds  
As applicable, a summary record with information on the test compound categories, 
chemical classes and sets tested during the method’s development, evaluations, PM 
development and /or validation (as applicable) is expected in this section. In particular the 
rationale for the choice of the given test compounds/reference chemicals/chemical 
libraries/test materials/nano-materials/ pharmaceuticals or other products.  
The paragraph should include the references to the sources where the detailed lists of the 
tested compounds and results are published and/or made available and to which level of 
detail: e.g. names, MOL files, CAS umbers, IUPAC names, InCHI codes, availability from 
commercial sources, composition (for mixtures) characteristics/properties (for nano-
materials) and the endpoint values obtained and unit of the raw data. If the access to data 
is restricted, the reason why should be stated.  
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Predictive capacity  
Available information on the predictive capacity of the method should be provided here, 
with respect to its ability to measure or predict the effect/event/mechanism/response of 
interest with the test compounds for which the method has been intended. If available, the 
following accuracy values should be included: overall accuracy, sensitivity, specificity, 
positive and negative predictive values, false positive and negative proportions, 
comments on any unexpected outcome as appropriate and indication of preliminary 
evaluations performed. 
Applicability 
Brief description of the types of test material that are compatible with the method and/or 
for which the method has been intended and judged as appropriate, based on the 
available evidence and indicating possible limitations. 
If possible, the applicability domain may be characterised and suggested by e.g.: use 
classes (chemicals (full spectrum, specific types and with specific uses), vaccines, 
hormones, medical devices) or physicochemical descriptors (e.g. in case of 
nanomaterials). 
Issues encountered with any chemical classes during a study should be listed, whether it 
is not suitable or requires extra precautions (e.g. volatile, viscous, highly coloured or low 
solubility compounds).  
In cases when only a limited number of substances (i.e.<10) would have been tested up 
to now, a list of the substances by names, grouped in logical chemical group/categories 
should be provided.  
 
NOTE: Additional documents/data sets can be uploaded to this Method Description for 
further clarification. The section is also interlinked with the Test Results DB-ALM data 
sector where experimental data can eventually be entered/uploaded. 
 
4. Discussion 
Comments should be provided in brief on the following factors (as appropriate): 
Ethical issues and considerations for 3R’s impact  
- e.g., use of animals to obtain primary cells, use of human stem cells  
Known strength and/or limitations of the method 
- Duration and complexity of the test 
- Costs (approximate cost for testing e.g. 10 compounds)  
- Comparison of the method to other similar assays (if known) that may 
characterise the same endpoint/key event as described in Procedure 
Description section  
- Eventual advantages, issues/limitations of the experimental system (amenable 
to cryopreservation or only freshly or prepared, availability, reproducibility over 
time) 
- Not suitable for certain classes of chemicals 
Technical requirements 
- Technical complexity of the method regarding special equipment, controlled 
environment, software and amount of training required 
Modifications of the method 
- Known differences in conducting this method, identified from different/same 
research group(s) and the rationale   
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Potential for future development 
- Potential of the method  for up-scaling and/or automation   
- Other on-going developments  
Comparisons to other methods 
- As appropriate indication/comparison to other method developments or related 
Additional Considerations 
- Indication of information not covered by the previous headings 
 
 
5. Contact Details  
Contact details of persons and organisations familiar with the method (authors, 
developers or experienced users).  
 
To be listed in the following format: 
 
Contact Person(s):  
Function:  
- Method developer/user 
- Data sheet provider  
Full Address: 
Tel: 
E-mail: 
Contact Person: 
Function: (see above) 
Full Address: 
Tel: 
E-mail: 
Versioning: 
Name Type of changes Version number Date 
 
6. Abbreviations & Definitions 
To be listed in an alphabetical order for all key terms included in the method summary and 
using the following format:  
NRR: Neutral Red Release 
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7. Bibliography 
 Method development 
List of all bibliographic references to original paper(s) explaining the method development 
(cited in the Section: Scientific Principle of the Method). 
 General 
Reports useful references other than those directly associated with the assay or prediction 
model development. 
 
All cited articles and other sources should be listed in accordance with the rules of the 
data entry format of the content management system of the DB-ALM 
Last Update: Last data sheet revision   
NOTE: All indications or eventual statements shall be supported with references within the text 
and full details listed under “Bibliographic References” data sector.  
© European Union 2006-2016 
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DB-ALM Content Criteria - Glossary 
3Rs:  
Reduction (of animal use); Refinement (to lessen pain or distress and to enhance 
animal well-being); and Replacement (of an animal test with one that uses non-animal 
systems or phylo-genetically lower species). 
AOP: Adverse Outcome Pathway 
For comprehensive information on the concept and realisation of the Adverse 
Outcome Pathway conceptual framework, access at: 
 OECD Adverse Outcome Pathways: Molecular Screening and Toxicogenomics 
 https://aopkb.org/ 
Biological Endpoint:  
Comprises biological processes, responses or effects assessed by a given method. 
The techniques used to assess the biological endpoint are referred to as endpoint 
measurement.  
CAS number: Chemical Abstract Service Registry is a unique numeric identifier that 
designates only one substance and has no chemical significance. 
Category formation and read-across: The outcomes from the assay could be used 
to substantiate a hypothesis for grouping substances together for the purposes of 
read-across; see also  
 OECD Guidance for Describing Non-guideline in vitro Test Methods 
DB-ALM: EURL ECVAM DataBase service on ALternative Methods to animal 
experimentation; access at:  
 http://ecvam-dbalm.jrc.ec.europa.eu  
GHS: Globally Harmonized System of Classification and Labeling of Chemicals, an 
internationally agreed-upon system, created and implemented by the United Nations. 
IATA: Integrated approaches to testing and assessment  
The method described may form one component of an IATA; A detailed example and 
description of the concept and the realization of IATA can be found here:  
 http://www.oecd.org/env/ehs/testing/ 
ICH: The International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use, a trilateral (EU-Japan-USA) 
programme bringing together the regulatory authorities and pharmaceutical industry 
to discuss scientific and technical aspects of drug registration 
 www.ich.org 
InCHI code: The IUPAC International Chemical Identifier, a non-proprietary identifier 
for chemical substances that can be used in printed and electronic data sources thus 
enabling easier linking of diverse data compilations. 
ITS: Integrated Testing Strategies; the objective of an ITS is to give guidance on a 
stepwise approach to hazard identification with regard to a given endpoint; a key 
principle of the strategy is that the results of one study are evaluated before another is 
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initiated. The strategy should seek to ensure that the data requirements are met in the 
most efficient and humane manner so that animal usage and costs are minimised. 
(ECHA, Guidance on Information Requirements and Chemical Safety Assessment)  
 Chapter R.7a: Endpoint specific guidance  
IUPAC: The International Union of Pure and Applied Chemistry 
LOEL: Lowest Observed Effect Level 
MIE: Molecular Initiating Event 
The first point of chemical- biological interaction within an organism which starts the 
adverse outcome pathway. 
MOL: A file format for holding information about the atoms, bonds, connectivity and 
coordinates of a molecule  
NOEL: No Observed Effect Level 
The level of exposure of an organism, at which there is no biologically or statistically 
significant effects when compared to the appropriate control 
Priority setting: The assay might help prioritise substances within an inventory for 
more detailed evaluation; see also  
 OECD Guidance for Describing Non-guideline in vitro Test Methods 
REACH: EU Regulation (EC) No 1907/2006 concerning the Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH), establishing a European 
Chemicals Agency 
 http://echa.europa.eu/support/testing-methods-and-alternatives 
Robust(ness): The insensitivity of test results to departures from the specified test 
conditions when conducted in different laboratories or over a range of conditions 
under which the test method might normally be used. If a test is not robust, it will be 
difficult to use in a reproducible manner within and between laboratories (see also 
OECD Series on Testing and Assessment Nr 34: Guidance Document on the 
Validation and International Acceptance of New or Updated Test Methods for Hazard 
Assessment). 
 http://www.oecd.org/env/ehs/testing/ 
Validation: The process by which the reliability and relevance of a particular 
approach, method, process or assessment is established for a defined purpose. A 
novel method can become a candidate for further validation studies and 
standardisation in order to achieve international acceptance (see also OECD Series 
on Testing and Assessment Nr 34: “Guidance Document on the Validation and 
International Acceptance of New or Updated Test Methods for Hazard Assessment”) 
 http://www.oecd.org/env/ehs/testing/ 
VICH: The International Cooperation on Harmonisation of Technical Requirements for 
Registration of Veterinary Medicinal Products, a trilateral (EU-Japan-USA) 
programme aimed at harmonising technical requirements for veterinary product 
registration 
 www.vichsec.org 
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7.4 ANNEX IV:  
Software Developments for System Evolution 
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DB-ALM version 2014/15/16 
The following updates were made to the DB-ALM version 2014/15/16 and put live. 
 Added major improvements to the free text search for Methods, especially 
those using logical operators e.g. AND, OR etc. 
Search finds results in  
o topic name 
o method name 
o method body 
o biological endpoint terms and measurements 
o experimental system terms and descriptions 
o compound names, trade names, synonyms, CAS and EC numbers 
o bibliography titles and authors 
o contact names 
o institution names 
o statuses 
o models 
o areas 
 Resumes were completely re-developed. They are now a first class citizen with 
their own table and can exist independently of Protocols 
 A Method number was added to Method Summaries with the ability to search 
for  that number 
 The Registration procedure was redeveloped. This including the forgotten 
password function and Account update page 
 Added the ability to sort Method results by Models & Strategies, Experimental 
System and Regulatory Status 
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 Added the ability to create a Method summary in OECD compliant structure 
and view and convert existing Method Summaries to OECD format 
 
 
Figure 4: The screen capture of the DB-ALM Content Management System, showing 
the settings for applying new Content Criteria.  
 Added printing for Topic Summary list, Methods list, Glossary list and Home 
pages 
 Improved the usability of results page. When scrolling, the EU header scrolls 
off the page but the search options stay visible at the top of the page. 
 Redesigned and implemented the layout the compound list displayed inline and 
in a popup 
 Added a feedback questionnaire 
 Based on user feedback modification to the layout of the menus and content 
on home page were made 
 All items can be published from the new admin system, Topics, Method 
summaries, Protocols, Validation studies, Resumes, Evaluation studies, 
Contacts, Biblios, Sources, Acronyms, Publishers, Experimental systems, 
Endpoints, Compounds, Test results, Study participants, Study labs, Study 
compounds, Study test results 
 All actions of the website visitors are logged from now on.  This allows us to 
analyse exactly how users are using the website and perhaps make 
improvements in the future. 
 Created a preview of a log analysis tool to report DB-ALM website usage 
 Created a virtual machine with Windows 10 for testing with new MS Edge 
browser 
 Moved all log tables to separate oracle user and table space for each 
environment e.g. staging, pre-public, public for better separation on 
environments and security 
 Moved all security tables to separate oracle user and table space for each 
environment e.g. staging, pre-public, public for better separation on 
environments and security 
 Replaced one poorly designed and very complicated database table that holds 
study information for Validation study/protocols with six separate tables. The 
new design also caters for the ability to have study information for Validation 
study/Method summaries 
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 Changed the website to run HTTPS using the JRC reverse proxy 
 Made server configuration changes to improved security 
 
 
The following updates were made to the DB-ALM version 2014/15/16 in staging and 
are ready to go live in the course of 2016: 
 
 The remaining sections of the old website were moved to  /pre and made the 
/beta website the main site. This work included also additional changes and 
improvement to the  service: 
1. Added pages Links, Faq, Privacy Statement 
2. Sub-pages on home page e.g. related projects, now have their own 
page/URL 
3. Added Projects and Studies section 
4. Added People and Institutions section 
5. Added Bibliography section 
6. Improved search engine optimisation by removing index.cfm from URL, 
giving each page a friendly human readable URL 
7. Improved search engine optimisation by giving all free text searches, 
filters, sorts etc. a friendly URL that can be linked to from other sites and 
indexed by search engines 
8. Converted the javascript to typescript/ES6 and rewrote to make code more 
generic, clean, and reusable 
9. Redesigned the CSS usage and page layout 
10. Added support for mobile devices 
11. Added favicons and configuration files for apple, android and microsoft 
devices 
12. Added facebook and twitter metadata so links to DB-ALM on their sites 
display our branding and content 
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7.5 ANNEX V: Bibliographic Citations 
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BOOKS published in 2014-2016 referring to the BD-ALM 
as information resource 
 Books search engine) (conducted on 22.06.2016; using Google
 
1. Gruiz, K., Meggyes, T., and Fenyvesi, E. (2015). Engineering Tools for Environmental Risk 
Management: 2. Environmental Toxicology (CRC Press). 
 
The book contains numerous references to the DB-ALM in the chapters on 
Carcinogenity, Genotoxicity, Eye Irritation and Corrosion and Toxicokinetics:  
 
- Page 138 » 
 
- Page 144 » 
 
- Page 145 » 
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- Page 148 » 
 
- Page 156 
... Table 3.15 In vitro ocular test methods considered valid for limited regulatory  
testing (OECD, 2014; DB-ALM, 2014). ... ECVAM DB-ALM Protocol No.85  
Isolated Rabbit Eye (IRE) assay Eye corrosion Ongoing/CLP R41 DB-ALM  
Protocol ... 
- Page 159 
The permeability is expressed as apparent permeability coefficient (Papp) (DB- 
ALM Protocol No.142); – Metabolic Stability assay can be used to rank the test  
compounds with respect to their metabolic stability or biotransformation. 
- Page 160 
ECVAM DB-ALM established a protocol titled: “Whole Rat Brain Reaggregate  
Spheroid Culture''. This culture system (single cell Table 3.19 In vivo testing of  
endocrine disrupting effect of 160 Engineering Tools for Environmental Risk ... 
- Page 161 
... for Detection of Estrogenic Agonist-Activity of Chemicals suspension) allows  
the testing of neurotoxic compounds during development, differentiation and  
relative maturity of the brain reaggregate (DB-ALM Protocol No.11 (DB-ALM,  
2014). 
- Page 165 
DB-ALM Protocol No 101. [Online] Available from: http://ecvam-dbalm.jrc.ec. 
europa.eu. [Accessed 20th October 2013]. Coecke, S., Blaauboer, B.J., Elaut, G.  
et al. (2005) Toxicokinetics and metabolism. Alternatives to Laboratory Animals,  
33(1) ... 
- Page 166 
ECVAM-DB-AL INVITTOX protocol. [Online] Available from: http:// ecvam-dbalm. 
jrc.ec.europa.eu/public_view_doc.cfm?id=6E7E72104B2DEFD6BE979B3B13  
9176C67180BB0BC12CB10496CDA74B54630A05A3291B895581F634. 
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2. Harbison, R.D., Bourgeois, M.M., and Johnson, G.T. (2015). Hamilton and Hardy’s 
Industrial Toxicology (John Wiley & Sons). 
 
Makes references to a number of DB-ALM protocols: 
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3. Baki, G., and Alexander, K.S. (2015). Introduction to Cosmetic Formulation and 
Technology (John Wiley & Sons). 
 Source of citations: 
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4. Kleinjans, J. (2014). Toxicogenomics-Based Cellular Models: Alternatives to Animal 
Testing for Safety Assessment (Academic Press). 
 
Source of citations: 
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5. Monteiro-Riviere, N.A., and Tran, C.L. (2014). Nanotoxicology: Progress toward 
Nanomedicine, Second Edition (CRC Press). 
Source of citations: 
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OECD Test Guidelines and drafts published in 2015 
referring to the DB-ALM 
) (search conducted on 22.06.2016 on the OECD website
 
1. OECD TG 422D: Kreatinosens 
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2. OECD TG 442C –DPRA: 
 
 
 
3. OECD TG 492: EpiOcular:
 
 
 
4. Draft h-Clat test guideline –  
http://www.oecd.org/env/ehs/testing/151216-Draft-h-CLAT-TG-After-Expert-Meeting-(clean)-
Final.pdf 
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5. OECD TG 430-Ter. Updated in 2015: 
 
The text refers to the SOP available from the DD-ALM: 
 
6. OECD TG 431- Rhe Skin Corrosion updated in 2015: 
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Refers to a number of protocols available from DB-ALM:
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OECD Guidance documents (released in 2015) 
 
1. DRAFT Guidance Document  In Vitro Bhas 42 Cell Transformation 
Assay  
available from 
https://www.google.com/url?q=http://www.oecd.org/env/ehs/testing/Bhas%2520
42%2520CTA%2520GD%2520after%25203rd%2520comments-
F_CLEAN.pdf&sa=U&ved=0ahUKEwi92OfC5KnKAhUnnnIKHfAqDOc4ChAWCBEwBA
&client=internal-uds-cse&usg=AFQjCNGD7KUQALT13faa07SlRjMsocYiNg) 
 
 
2. Guidance Document On The In Vitro Syrian Hamster Embryo (She) 
Cell Transformation Assay Series on Testing & Assessement No. 214 : 
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Top 15 of Websites redirecting to DB-ALM 
(period Jan 2014- June 2016)  
1.  http://www.shiseidogroup.jp/rd/safety/test/hclat.html 
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3.  http://ihcp.jrc.ec.europa.eu/our_activities/alt-animal-testing-safety-assessment- 
chemicals/now-online-entirely-revised-db-service-on-alternative-methods 
4. http://cosmed.knowings.com/cosmed/bc.nsf/0/e3dd0016a5c38bf4c1257d620051f9f4?o
penDocument 
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